IRA Drug Price Negotiation Round Three Selections Announced in October 2026 Are Forcing Pharma Pricing Strategy Reassessment Across Biologics and Small-Molecule Portfolios

The Centers for Medicare and Medicaid Services announced the Round 3 selections for Medicare drug price negotiation under the Inflation Reduction Act in early October 2026, identifying fifteen additional drugs across both small-molecule and biological categories for negotiated maximum fair pricing that will take effect in 2028. The Round 3 selections extend the IRA negotiation programme beyond the cardiovascular, diabetes, and blood thinner categories that dominated early rounds into oncology, immunology, and rare disease biologics that represent a larger share of pharmaceutical company revenue and that have historically operated with the greatest pricing freedom in US markets. The announcement has triggered immediate assessment exercises across pharmaceutical companies to quantify the revenue impact of negotiated pricing on selected drugs and to determine what changes to launch sequencing, lifecycle management, and indication expansion strategy are warranted by the revised revenue trajectory that negotiated pricing implies.

Round 3 Drug Selection Methodology and Surprises

CMS's selection methodology for IRA negotiation focuses on Medicare Part B and Part D spending concentration, selecting drugs with the highest Medicare expenditure that have been on market beyond the statutory exclusion periods that protect drugs from negotiation for seven years for small molecules and eleven years for biologics from first approval. The Round 3 selections were broadly anticipated by pharmaceutical industry analysts who had modelled the spending concentration thresholds, but several specific inclusions were regarded as earlier than the industry consensus had projected, particularly in the immunology space where two drugs with significant Medicare Part B spending were selected despite biologic exclusion period arguments that their manufacturers had made publicly and in submitted comments during the selection process.

The maximum fair price negotiation process that follows selection involves CMS making an initial offer based on an initial price applicability year calculation and the manufacturer submitting a counteroffer, with a formal negotiation period that has resulted in negotiated prices ranging from a few percent to more than sixty percent below the list price in earlier rounds. The Round 3 outcomes will not be known until the formal negotiated prices are announced in 2027, but manufacturers with selected drugs are conducting internal scenario analyses based on the price reduction ranges observed in Rounds 1 and 2 to determine the revenue impact under different negotiation outcome assumptions, and these analyses are feeding into five-year financial planning cycles and into investor guidance processes that will begin incorporating IRA negotiation impacts into consensus earnings forecasts for the affected companies.

Portfolio Strategy Implications for Biologics

The inclusion of biologics in Round 3 after two rounds that were predominantly small-molecule focused has crystallised the strategic implications of IRA negotiation for the biopharmaceutical industry in ways that were theoretically understood but now require operational response. The eleven-year biologic protection window, while longer than the small-molecule seven-year window, is shorter than the commercial peak revenue period for many successful biologics that continue to grow in usage and price beyond year eleven from approval. A biologic that receives approval at year one, reaches revenue peak at years eight to twelve, and faces negotiation eligibility at year eleven is in the position of entering negotiation at or near its revenue peak, with the negotiated maximum fair price then locking in lower Medicare reimbursement for the remaining commercial life of the product.

Lifecycle management strategies that have traditionally extended biologic revenue through indication expansion, formulation changes, and patient access programme refinement are being reassessed in the context of IRA negotiation eligibility timelines. Additional indications approved after initial launch extend the eleven-year window only for the new indication, not for the original indication, creating a complex calculation of when indication expansion investment generates sufficient revenue outside the negotiation-affected original indication to justify the R&D spend required. Some companies are examining whether orphan drug designation strategies, which provide certain exemptions from IRA negotiation, can be incorporated into development plans for products in disease areas that could potentially qualify for rare disease status while also having broader population applications that generate significant Medicare spending.

Small-Molecule Impact and Launch Strategy Recalibration

For small-molecule drugs, the seven-year negotiation protection window is creating explicit launch sequencing considerations that were not part of pharmaceutical commercialisation strategy before the IRA. Companies with products approaching the seven-year threshold are examining whether accelerated revenue optimisation in years five through seven, through pricing, market access, and volume growth strategies, can more than offset the revenue reduction that negotiated pricing will impose in years eight and beyond. The net present value calculations underlying these trade-offs are complex and depend significantly on assumptions about the negotiated price reduction magnitude, the volume response to lower negotiated pricing in Medicare, and the commercial dynamics outside Medicare where negotiated pricing does not directly apply but where reference pricing effects may have indirect implications. Investment in launch economics optimisation within the pre-negotiation window has become a distinct strategic discipline that is attracting dedicated analytical resources at companies with drugs in years three through six of their commercial lifecycle.

The IRA negotiation programme is also influencing pharmaceutical company investment decisions about drug development pipeline composition. Analysis of the revenue economics of drug development under IRA negotiation has led several pharmaceutical companies to explicitly state that small-molecule drugs with high Medicare spending concentration are subject to a revised return on investment calculus that may make certain development investments less attractive relative to alternatives. Novel biologics in the rare disease space, where CMS's negotiation scope is more limited, and drugs targeting patient populations where Medicare spending concentration is lower have seen increased R&D investment attention as companies seek development portfolio compositions that generate competitive returns under the IRA framework. The aggregate effect of these individual company pipeline prioritisation decisions on the future drug development portfolio and on therapeutic area innovation investment is a policy externality that the pharmaceutical industry has raised extensively in public comment on IRA implementation and that academic researchers are beginning to study through patent application and clinical trial registration data. Whether the long-term innovation impact justifies the near-term drug pricing reduction achieved through IRA negotiation is a contested empirical and policy question that will take years to resolve but that is already influencing both the regulatory debate around potential IRA modifications and the investment calculus of pharmaceutical R&D capital allocators.

Top 10 Companies

1. Merck , US pharmaceutical company with Keytruda among the highest-spending oncology biologics in Medicare, whose exposure to Round 3 and future negotiation rounds is a central element of its long-term revenue sustainability analysis.
2. Bristol-Myers Squibb , Major oncology and immunology pharmaceutical company with several high-Medicare-spend biologics that fall within the IRA negotiation eligibility window and whose portfolio is subject to ongoing monitoring for future round selection.
3. Johnson and Johnson , Diversified healthcare company whose pharmaceutical division has high-spend immunology biologics including products in categories that Round 3 selections have targeted.
4. AbbVie , Pharmaceutical company whose post-Humira portfolio development is being evaluated against IRA negotiation timelines as it builds revenues from newer biologics that will enter the negotiation window during the next five to ten years.
5. Eli Lilly , Major pharmaceutical company with significant Medicare Part D spend on diabetes and obesity products that have attracted substantial regulatory and pricing policy attention and whose IRA exposure is closely monitored by investors.
6. Pfizer , Diversified pharmaceutical company with oncology, inflammation, and rare disease products in the spending concentration range that CMS has targeted in successive negotiation rounds.
7. Novartis , Swiss pharmaceutical company with US Medicare-relevant oncology and cardiovascular products whose IRA negotiation exposure is a factor in its US market revenue planning for the latter part of the decade.
8. Amgen , US biologics pioneer with a portfolio of established biologics in therapeutic areas that are increasingly within IRA negotiation scope as the programme extends into immunology and oncology categories.
9. Genentech / Roche , Major oncology biologics developer whose portfolio includes several high-Medicare-spend cancer biologics that represent significant IRA negotiation exposure in the current and prospective future selection rounds.
10. Centers for Medicare and Medicaid Services , Federal agency conducting the drug price negotiation programme whose selection methodology, negotiation process, and maximum fair price outcomes are the primary regulatory variables that determine IRA's revenue impact on pharmaceutical companies.